Turning Innovation into Action for Years.
 



On 1st April 2004 BioBridge celebrated 15 years of consultancy in strategy and practical issues for bioscience in the business context. Based in the centre of Cambridge, the practice has been at the forefront of bioscience developments since its start, embracing the range of the life science sectors. Highlights of the biotechnology and other trend-leading consultancy projects include:

1989 Biotechnology in animal production - where is it going?
1992 Biotechnology and its impact on food safety - new tools for food security
The structure and function of the proposed European Medicines Evaluation Agency
Regulation of crop agriculture - is there a future?
Innovation in aquaculture - challenges and opportunities
1995 Building a European network in new biomaterials - synergies and information flow
Building an internet resource for inward investment decisions in healthcare - business and product regulations in the UK
1996 Towards an ICH (International Conference on Harmonization) activity for Animal Health - VICH
Project management database for AMICA - Europe's biggest multicentre project in crop biotechnology research
European strategy for a mammalian cell-based liver support system - regulation and acceptance
1999 Due diligence for cell-based brain and bone therapies company for a regional investment company
In vivo monitoring start-up - getting to market
2000 Biotechnology and animal feed additives - grappling with the EU
ERBI's purchasing group - feasibility study and pilot scheme
  AIDS in Spain - the power of patient advocacy groups
2001 Due diligence of novel biomaterials company prior to LSE flotation for an investment bank
Stem cell products in Europe - how to establish viable businesses
Due diligence of a personal genome medicine investment for an investment group
2003 Science mission to Japan - tissue engineering and stem cells
Pittsburgh and tissue engineering mission
2004 Marine biotechnology in UK - prospects, challenges and opportunities
Business Plan evaluation of a company with a novel in vivo model for high throughput screening
  Science and Technology in Society - 1st Kyoto International Forum 2004